Metropolitan Life Insurance Co NY cut its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 1.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,298 shares of the company’s stock after selling 180 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in Omnicell were worth $994,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Parallel Advisors LLC acquired a new stake in shares of Omnicell during the first quarter valued at about $28,000. Nisa Investment Advisors LLC raised its position in shares of Omnicell by 125.0% during the first quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock worth $44,000 after acquiring an additional 300 shares during the last quarter. Manchester Capital Management LLC bought a new position in shares of Omnicell during the first quarter worth about $49,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Omnicell by 451.8% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock worth $38,000 after acquiring an additional 506 shares during the last quarter. Finally, Financial Gravity Wealth Inc. bought a new position in shares of Omnicell during the first quarter worth about $50,000. 97.02% of the stock is currently owned by institutional investors and hedge funds.
OMCL has been the topic of several research analyst reports. Zacks Investment Research raised Triple-S Management from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research report on Monday, April 29th. BidaskClub lowered Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, June 27th. Craig Hallum upgraded PROS from a “hold” rating to a “buy” rating and upped their target price for the stock from $36.00 to $60.00 in a research note on Friday, April 26th. ValuEngine upgraded Valmont Industries from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. Finally, TheStreet lowered Trinity Industries from a “b” rating to a “c” rating in a research note on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Omnicell presently has an average rating of “Buy” and a consensus target price of $79.89.
Shares of OMCL traded down $1.71 during midday trading on Thursday, reaching $69.59. The stock had a trading volume of 266,714 shares, compared to its average volume of 362,334. The business has a 50-day moving average price of $82.20. Omnicell, Inc. has a 12-month low of $52.20 and a 12-month high of $92.59. The company has a quick ratio of 1.47, a current ratio of 1.96 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $2.93 billion, a P/E ratio of 45.48, a price-to-earnings-growth ratio of 2.31 and a beta of 1.13.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.38. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The firm had revenue of $202.50 million during the quarter, compared to analysts’ expectations of $199.72 million. During the same period in the prior year, the business earned $0.29 EPS. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, equities analysts forecast that Omnicell, Inc. will post 2.06 earnings per share for the current fiscal year.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: Why do company’s buyback their stock?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.